<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><rec-number>6975</rec-number><ref-type>Journal Article</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McHenry, Leemon B.</style></author><author><style face="normal" font="default" size="100%">Jureidini, Jon N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study</style></title><secondary-title><style face="normal" font="default" size="100%">Accountability in Research: Policies &amp; Quality Assurance</style></secondary-title><short-title><style face="normal" font="default" size="100%">Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ACTIONS</style></keyword><keyword><style  face="normal" font="default" size="100%">Authorship</style></keyword><keyword><style  face="normal" font="default" size="100%">Central</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical</style></keyword><keyword><style  face="normal" font="default" size="100%">Conflict</style></keyword><keyword><style  face="normal" font="default" size="100%">final</style></keyword><keyword><style  face="normal" font="default" size="100%">GHOSTWRITING</style></keyword><keyword><style  face="normal" font="default" size="100%">GlaxoSmithKline</style></keyword><keyword><style  face="normal" font="default" size="100%">Human</style></keyword><keyword><style  face="normal" font="default" size="100%">industry-sponsored</style></keyword><keyword><style  face="normal" font="default" size="100%">key</style></keyword><keyword><style  face="normal" font="default" size="100%">MEDICINE</style></keyword><keyword><style  face="normal" font="default" size="100%">off-label</style></keyword><keyword><style  face="normal" font="default" size="100%">PAROXETINE</style></keyword><keyword><style  face="normal" font="default" size="100%">Paxil</style></keyword><keyword><style  face="normal" font="default" size="100%">primary</style></keyword><keyword><style  face="normal" font="default" size="100%">research</style></keyword><keyword><style  face="normal" font="default" size="100%">Scientific</style></keyword><keyword><style  face="normal" font="default" size="100%">secondary</style></keyword><keyword><style  face="normal" font="default" size="100%">serious</style></keyword><keyword><style  face="normal" font="default" size="100%">Seroxat)</style></keyword><keyword><style  face="normal" font="default" size="100%">SmithKline</style></keyword><keyword><style  face="normal" font="default" size="100%">University/Industry Collaboration</style></keyword></keywords><taxonomies><taxonomy><style  face="normal" font="default" size="100%">University/Industry Collaboration</style></taxonomy><taxonomy><style  face="normal" font="default" size="100%">Authorship</style></taxonomy><taxonomy><style  face="normal" font="default" size="100%">Medicine</style></taxonomy></taxonomies><pubtype><style  face="normal" font="default" size="100%">Journal Article</style></pubtype><audience-level><style  face="normal" font="default" size="100%">ug</style></audience-level><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">152-167</style></pages><issn><style face="normal" font="default" size="100%">08989621</style></issn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">In this case study from litigation, we show how ghostwriting of clinical trial results by industry can contribute to the manipulation of data to favor the study medication. </style></abstract><doi><style face="normal" font="default" size="100%">10.1080/08989620802194384</style></doi><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><accession-num><style face="normal" font="default" size="100%">32964890</style></accession-num><notes><style face="normal" font="default" size="100%">McHenry, Leemon B. 1; Email Address: leemon.mchenry@csun.edu; Jureidini, Jon N. 2; Affiliations: 1: Department of Philosophy, California State University, Northridge, Northridge, California, USA; 2: Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia; Issue Info: Jul-Sep2008, Vol. 15 Issue 3, p152; Thesaurus Term: ACTIONS &amp; defenses; Thesaurus Term: RESEARCH; Subject Term: GHOSTWRITING; Subject Term: CLINICAL trials; Subject Term: PAROXETINE; Subject Term: MEDICINE; Subject Term: HUMAN experimentation in medicine; Author-Supplied Keyword: Central Medical Affairs Team; Author-Supplied Keyword: clinical trials; Author-Supplied Keyword: conflict of interest; Author-Supplied Keyword: final clinical report; Author-Supplied Keyword: GlaxoSmithKline; Author-Supplied Keyword: industry-sponsored ghostwriting; Author-Supplied Keyword: key opinion leader; Author-Supplied Keyword: off-label prescriptions; Author-Supplied Keyword: paroxetine (Paxil; Author-Supplied Keyword: Paxil Team; Author-Supplied Keyword: primary efficacy variables; Author-Supplied Keyword: Scientific Therapeutics Information; Author-Supplied Keyword: secondary efficacy variables; Author-Supplied Keyword: serious adverse events; Author-Supplied Keyword: Seroxat); Author-Supplied Keyword: SmithKline Beecham; NAICS/Industry Codes: 541712 Reseach and Development in the Physical, Engineering, and Life Sciences (except Biotechnology); Number of Pages: 16p; Document Type: Article</style></notes></record></records></xml>